Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S 44121 versus placebo in CPVT type 1 during exercise testing
NL-OMON37671Phase 2Active, not recruiting
- Sponsor
- Servier
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of S44121 in catecholaminergic polymorphic ventricular tachycardia type 1 (CPVT1), sponsored by Servier. Primary endpoint: Mean number of premature ventricular contractions per minute during exercise testing. Started Dec 2011; status: active, not recruiting.
02
Drugs
S44121
03
Conditions
catecholaminergic polymorphic ventricular tachycardia type 1 (CPVT1)
Beyond the preview
Go deeper on NL-OMON37671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37671.